Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Study of TOP1630 for Dry Eye Syndrome
Phase 2
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: TOP1630 0.1% Ophthalmic Solution TID OUDrug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Topivert Pharma Ltd
- Target Recruit Count
- 202
- Registration Number
- NCT03833388
- Locations
- 🇺🇸
Central Maine Eye Care, Lewiston, Maine, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
🇺🇸Suite 305, 775 Paramount Drive, Raynham, Massachusetts, United States
Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Topivert Pharma Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT03071081
- Locations
- 🇬🇧
PAREXEL Early Phase Clinical Unit, London, United Kingdom
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Topivert Pharma Ltd
- Target Recruit Count
- 77
- Registration Number
- NCT02888379
Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Topivert Pharma Ltd
- Target Recruit Count
- 67
- Registration Number
- NCT02463045
- Locations
- 🇬🇧
CTU, London, United Kingdom
News
No news found